Royalty Pharma
RPRX
416 hedge funds and large institutions have $8.21B invested in Royalty Pharma in 2024 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 162 increasing their positions, 135 reducing their positions, and 50 closing their positions.
466% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $3.2M
54% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 50
20% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 135
5% more funds holding
Funds holding: 395 → 416 (+21)
2.54% more ownership
Funds ownership: 69.88% → 72.43% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
7% less capital invested
Capital invested by funds: $8.86B → $8.21B (-$651M)
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$134M |
| 2 |
BlackRock
New York
|
+$83.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$76.8M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$43.6M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$32.9M |
Top Sellers
| 1 |
SCM
Suvretta Capital Management
New York
|
-$52.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$52.7M |
| 3 |
Millennium Management
New York
|
-$51.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$45.8M |
| 5 |
Morgan Stanley
New York
|
-$41M |
RPRX Hedge Fund Activity: Q4 2024 in Review
416 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q4 2024, worth a combined $8.21B — down 7.3% from $8.86B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new RPRX positions and 50 closed out — a net gain of 27 holders — while 162 added to existing stakes and 135 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $134M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $52.8M sold.
- 416 institutional investors held Royalty Pharma (RPRX) as of Q4 2024, up from 395 in Q3 2024.
- Funds reported $8.21B of Royalty Pharma stock for Q4 2024, down 7.3% quarter-over-quarter.
- 77 funds opened new Royalty Pharma positions in Q4 2024 and 50 closed out, a net change of +27 holders.
- The largest Royalty Pharma buyer in Q4 2024 was Adage Capital Partners, an estimated $134M added.
- The largest Royalty Pharma seller in Q4 2024 was Suvretta Capital Management, an estimated $52.8M sold.
Based on aggregated 13F filings for Q4 2024.